Etomidate Injection · ETOMIDATE 2 mg/mL · Solution · Intravenous · Gland Pharma Limited
NDC 68083-0234-10 · 10 VIAL in 1 CARTON / 10 mL in 1 VIAL · ANDA · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Fosun Pharma USA Inc | ETOMIDATE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Gland Pharma Limited | ETOMIDATE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Etomidate — NDC 68083-0234-10," retrieved September 3, 2026, https://drugdashboards.com/drug/68083023410.
Free to cite with attribution — see how the data is put together.